We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Akorn Inc | NASDAQ:AKRX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.09 | 0.1398 | 0.1399 | 0 | 01:00:00 |
þ
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
|
|
FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2017
|
|
|
o
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
LOUISIANA
|
72-0717400
|
(State or Other Jurisdiction of
|
(I.R.S. Employer
|
Incorporation or Organization)
|
Identification No.)
|
|
|
1925 W. Field Court, Suite 300
|
|
Lake Forest, Illinois
|
60045
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
Yes
|
þ
|
|
No
|
o
|
Yes
|
þ
|
|
No
|
o
|
Yes
|
o
|
|
No
|
þ
|
|
|
|
Page
|
PART I. FINANCIAL INFORMATION
|
|
ITEM 1. Financial Statements (unaudited).
|
|
Condensed Consolidated Balance Sheets - June 30, 2017 and December 31, 2016
|
|
Condensed Consolidated Statements of Comprehensive Income - Three and Six months ended June 30, 2017 and 2016
|
|
Condensed Consolidated Statement of Shareholders’ Equity - Six months ended June 30, 2017
|
|
Condensed Consolidated Statements of Cash Flows - Six months ended June 30, 2017 and 2016
|
|
PART II. OTHER INFORMATION
|
|
|
|
SIGNATURES
|
|
|
|
EXHIBIT INDEX
|
|
|
June 30, 2017 (Unaudited)
|
|
December 31, 2016
|
||||
ASSETS
|
|
|
|
||||
CURRENT ASSETS
|
|
|
|
||||
Cash and cash equivalents
|
$
|
322,742
|
|
|
$
|
200,772
|
|
Trade accounts receivable, net
|
177,591
|
|
|
283,154
|
|
||
Inventories, net
|
181,549
|
|
|
174,793
|
|
||
Available-for-sale securities, current
|
—
|
|
|
1,106
|
|
||
Prepaid expenses and other current assets
|
22,008
|
|
|
25,986
|
|
||
TOTAL CURRENT ASSETS
|
703,890
|
|
|
685,811
|
|
||
PROPERTY, PLANT AND EQUIPMENT, NET
|
276,936
|
|
|
238,404
|
|
||
OTHER LONG-TERM ASSETS
|
|
|
|
|
|
||
Goodwill
|
285,054
|
|
|
284,293
|
|
||
Intangible assets, net
|
720,000
|
|
|
758,854
|
|
||
Deferred tax assets
|
8,225
|
|
|
5,286
|
|
||
Other non-current assets
|
2,239
|
|
|
1,072
|
|
||
TOTAL OTHER LONG-TERM ASSETS
|
1,015,518
|
|
|
1,049,505
|
|
||
TOTAL ASSETS
|
$
|
1,996,344
|
|
|
$
|
1,973,720
|
|
LIABILITIES AND SHAREHOLDERS’ EQUITY
|
|
|
|
|
|
||
CURRENT LIABILITIES
|
|
|
|
|
|
||
Trade accounts payable
|
$
|
42,770
|
|
|
$
|
59,534
|
|
Purchase consideration payable
|
4,994
|
|
|
4,994
|
|
||
Income taxes payable
|
2,832
|
|
|
16,198
|
|
||
Accrued royalties
|
4,304
|
|
|
15,044
|
|
||
Accrued compensation
|
17,244
|
|
|
19,113
|
|
||
Accrued administrative fees
|
29,017
|
|
|
36,436
|
|
||
Accrued expenses and other liabilities
|
27,699
|
|
|
24,236
|
|
||
TOTAL CURRENT LIABILITIES
|
128,860
|
|
|
175,555
|
|
||
LONG-TERM LIABILITIES:
|
|
|
|
|
|
||
Long-term debt (net of non-current deferred financing costs)
|
812,587
|
|
|
809,979
|
|
||
Deferred tax liability
|
157,867
|
|
|
157,607
|
|
||
Other long-term liabilities
|
11,758
|
|
|
11,395
|
|
||
TOTAL LONG-TERM LIABILITIES
|
982,212
|
|
|
978,981
|
|
||
TOTAL LIABILITIES
|
1,111,072
|
|
|
1,154,536
|
|
||
SHAREHOLDERS’ EQUITY
|
|
|
|
|
|
||
Common stock, no par value – 150,000,000 shares authorized; 124,858,261 and 124,390,217 shares issued and outstanding at June 30, 2017 and December 31, 2016, respectively
|
538,600
|
|
|
521,860
|
|
||
Retained earnings
|
362,855
|
|
|
319,291
|
|
||
Accumulated other comprehensive loss
|
(16,183
|
)
|
|
(21,967
|
)
|
||
TOTAL SHAREHOLDERS’ EQUITY
|
885,272
|
|
|
819,184
|
|
||
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY
|
$
|
1,996,344
|
|
|
$
|
1,973,720
|
|
|
Three Months Ended
June 30, |
|
Six Months Ended
June 30, |
||||||||||||
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||||||
Revenues, net
|
$
|
199,140
|
|
|
$
|
280,734
|
|
|
$
|
452,560
|
|
|
$
|
549,081
|
|
Cost of sales (exclusive of amortization of intangibles, included within operating expenses below)
|
96,173
|
|
|
108,961
|
|
|
200,461
|
|
|
214,291
|
|
||||
GROSS PROFIT
|
102,967
|
|
|
171,773
|
|
|
252,099
|
|
|
334,790
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Selling, general and administrative expenses
|
53,923
|
|
|
53,971
|
|
|
101,449
|
|
|
103,057
|
|
||||
Acquisition-related costs
|
76
|
|
|
136
|
|
|
87
|
|
|
333
|
|
||||
Research and development expenses
|
15,876
|
|
|
8,868
|
|
|
27,167
|
|
|
18,347
|
|
||||
Amortization of intangibles
|
15,504
|
|
|
16,430
|
|
|
30,975
|
|
|
32,948
|
|
||||
Impairment of intangible assets
|
3,058
|
|
|
—
|
|
|
3,058
|
|
|
158
|
|
||||
TOTAL OPERATING EXPENSES
|
88,437
|
|
|
79,405
|
|
|
162,736
|
|
|
154,843
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
||||
OPERATING INCOME
|
14,530
|
|
|
92,368
|
|
|
89,363
|
|
|
179,947
|
|
||||
Amortization of deferred financing costs
|
(1,304
|
)
|
|
(1,872
|
)
|
|
(2,608
|
)
|
|
(8,183
|
)
|
||||
Interest expense, net
|
(9,380
|
)
|
|
(10,768
|
)
|
|
(18,946
|
)
|
|
(22,286
|
)
|
||||
Other non-operating income (expense), net
|
2,904
|
|
|
547
|
|
|
4,267
|
|
|
(2,631
|
)
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
||||
INCOME BEFORE INCOME TAXES
|
6,750
|
|
|
80,275
|
|
|
72,076
|
|
|
146,847
|
|
||||
Income tax provision
|
4,213
|
|
|
18,282
|
|
|
28,512
|
|
|
42,968
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
||||
CONSOLIDATED NET INCOME
|
$
|
2,537
|
|
|
$
|
61,993
|
|
|
$
|
43,564
|
|
|
$
|
103,879
|
|
CONSOLIDATED NET INCOME PER SHARE
|
|
|
|
|
|
|
|
|
|
|
|
||||
CONSOLIDATED NET INCOME PER SHARE, BASIC
|
$
|
0.02
|
|
|
$
|
0.51
|
|
|
$
|
0.35
|
|
|
$
|
0.86
|
|
CONSOLIDATED NET INCOME PER SHARE, DILUTED
|
$
|
0.02
|
|
|
$
|
0.50
|
|
|
$
|
0.35
|
|
|
$
|
0.83
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
SHARES USED IN COMPUTING NET INCOME PER SHARE
|
|
|
|
|
|
|
|
|
|
|
|
||||
BASIC
|
124,660
|
|
|
121,374
|
|
|
124,541
|
|
|
120,401
|
|
||||
DILUTED
|
125,194
|
|
|
125,924
|
|
|
124,855
|
|
|
125,934
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
||||
COMPREHENSIVE INCOME
|
|
|
|
|
|
|
|
|
|
|
|
||||
Consolidated net income
|
$
|
2,537
|
|
|
$
|
61,993
|
|
|
$
|
43,564
|
|
|
$
|
103,879
|
|
Unrealized holding gain on available-for-sale securities, net of tax of ($85) and ($961) for the three months ended June 30, 2017 and 2016. ($160) and ($575) for the six month periods ended June 30, 2017 and 2016 respectively.
|
144
|
|
|
1,629
|
|
|
272
|
|
|
975
|
|
||||
Foreign currency translation gain (loss)
|
1,239
|
|
|
(1,308
|
)
|
|
5,265
|
|
|
(439
|
)
|
||||
Pension liability adjustment gain (loss), net of tax of ($6) and $694 for the three months ended June 30, 2017 and 2016, and ($63) and $694 for the six month periods ended June 30, 2017 and 2016 respectively.
|
24
|
|
|
(2,727
|
)
|
|
247
|
|
|
(2,727
|
)
|
||||
COMPREHENSIVE INCOME
|
$
|
3,944
|
|
|
$
|
59,587
|
|
|
$
|
49,348
|
|
|
$
|
101,688
|
|
|
|
Shares
|
|
Common Stock
|
|
Retained
Earnings
|
|
Other
Comprehensive
Loss
|
|
Total
|
|||||||||
BALANCES AT DECEMBER 31, 2016
|
|
124,390
|
|
|
$
|
521,860
|
|
|
$
|
319,291
|
|
|
$
|
(21,967
|
)
|
|
$
|
819,184
|
|
Consolidated net income
|
|
—
|
|
|
—
|
|
|
43,564
|
|
|
—
|
|
|
43,564
|
|
||||
Exercise of stock options
|
|
459
|
|
|
7,060
|
|
|
—
|
|
|
—
|
|
|
7,060
|
|
||||
Restricted stock units
|
|
14
|
|
|
3,037
|
|
|
—
|
|
|
—
|
|
|
3,037
|
|
||||
Stock-based compensation expense - stock options
|
|
—
|
|
|
6,270
|
|
|
—
|
|
|
—
|
|
|
6,270
|
|
||||
Foreign currency translation gain
|
|
—
|
|
|
—
|
|
|
—
|
|
|
5,265
|
|
|
5,265
|
|
||||
Stock compensation plan withholdings for employee taxes
|
|
(5
|
)
|
|
(164
|
)
|
|
—
|
|
|
—
|
|
|
(164
|
)
|
||||
Unrealized holding gain on available-for-sale securities
|
|
—
|
|
|
—
|
|
|
—
|
|
|
272
|
|
|
272
|
|
||||
Akorn AG pension liability adjustment
|
|
—
|
|
|
—
|
|
|
—
|
|
|
247
|
|
|
247
|
|
||||
Employee stock purchase plan
|
|
—
|
|
|
537
|
|
|
—
|
|
|
—
|
|
|
537
|
|
||||
BALANCES AT JUNE 30, 2017 (unaudited)
|
|
124,858
|
|
|
$
|
538,600
|
|
|
$
|
362,855
|
|
|
$
|
(16,183
|
)
|
|
$
|
885,272
|
|
|
Six Months Ended
June 30, |
||||||
|
2017
|
|
2016
|
||||
OPERATING ACTIVITIES:
|
|
|
|
||||
Consolidated net income
|
$
|
43,564
|
|
|
$
|
103,879
|
|
Adjustments to reconcile consolidated net income to net cash provided by operating activities:
|
|
|
|
|
|
||
Depreciation and amortization
|
42,212
|
|
|
44,111
|
|
||
Amortization of debt financing costs
|
2,608
|
|
|
8,152
|
|
||
Impairment of intangible assets
|
8,079
|
|
|
158
|
|
||
Non-cash stock compensation expense
|
9,844
|
|
|
6,446
|
|
||
Non-cash interest expense
|
—
|
|
|
764
|
|
||
Income from Available for sale securities
|
(3,032
|
)
|
|
—
|
|
||
Deferred income taxes, net
|
(2,341
|
)
|
|
(9,724
|
)
|
||
Loss on sale of available-for-sale securities
|
196
|
|
|
45
|
|
||
Other
|
(288
|
)
|
|
(780
|
)
|
||
Changes in operating assets and liabilities:
|
|
|
|
|
|
||
Trade accounts receivable
|
105,848
|
|
|
(54,296
|
)
|
||
Inventories, net
|
(6,225
|
)
|
|
(2,652
|
)
|
||
Prepaid expenses and other current assets
|
3,076
|
|
|
(23,421
|
)
|
||
Trade accounts payable
|
(13,465
|
)
|
|
4,778
|
|
||
Accrued expenses and other liabilities
|
(30,051
|
)
|
|
(41,383
|
)
|
||
NET CASH PROVIDED BY OPERATING ACTIVITIES
|
$
|
160,025
|
|
|
$
|
36,077
|
|
INVESTING ACTIVITIES:
|
|
|
|
|
|
||
Proceeds from disposal of assets
|
4,811
|
|
|
5,966
|
|
||
Payments for intangible assets
|
(200
|
)
|
|
(3,375
|
)
|
||
Purchases of property, plant and equipment
|
(50,072
|
)
|
|
(29,726
|
)
|
||
NET CASH USED IN INVESTING ACTIVITIES
|
$
|
(45,461
|
)
|
|
$
|
(27,135
|
)
|
FINANCING ACTIVITIES:
|
|
|
|
|
|
||
Proceeds from the exercise of stock options
|
6,897
|
|
|
6,176
|
|
||
Debt financing costs
|
—
|
|
|
(5,128
|
)
|
||
Debt payments
|
—
|
|
|
(200,000
|
)
|
||
NET CASH PROVIDED BY(USED IN) FINANCING ACTIVITIES
|
$
|
6,897
|
|
|
$
|
(198,952
|
)
|
Effect of exchange rate changes on cash and cash equivalents
|
509
|
|
|
38
|
|
||
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS
|
$
|
121,970
|
|
|
$
|
(189,972
|
)
|
Cash and cash equivalents at beginning of period
|
200,772
|
|
|
346,266
|
|
||
CASH AND CASH EQUIVALENTS AT END OF PERIOD
|
$
|
322,742
|
|
|
$
|
156,294
|
|
SUPPLEMENTAL DISCLOSURES:
|
|
|
|
|
|
||
Amount paid for interest
|
$
|
22,124
|
|
|
$
|
21,860
|
|
Amount paid for income taxes, net
|
$
|
43,901
|
|
|
$
|
100,801
|
|
Additional capital expenditures included in accounts payable
|
$
|
8,806
|
|
|
$
|
43,214
|
|
-
|
Level 1
—Assets and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable inputs, such as quoted prices in active markets for identical assets or liabilities. The carrying value of the Company's cash and cash equivalents and the portion of the value of the Nicox S.A. ("Nicox") shares which are available to be traded on the exchange are considered Level 1 assets.
|
-
|
Level 2
—Inputs to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms, as well as directly or indirectly observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals. The Company has no Level 2 assets or liabilities in any of the periods presented.
|
-
|
Level 3
—Inputs to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities. The portion of the fair
|
|
|
|
Fair Value Measurements at Reporting Date, Using:
|
||||||||||||
Description
|
June 30, 2017
|
|
Quoted Prices
in Active
Markets for
Identical Items
(Level 1)
|
|
Significant
Other
Observable
Inputs
(Level 2)
|
|
Significant
Unobservable
Inputs
(Level 3)
|
||||||||
Cash and cash equivalents
|
$
|
322,742
|
|
|
$
|
322,742
|
|
|
$
|
—
|
|
|
$
|
—
|
|
Nicox stock with lockup provisions
|
43
|
|
|
—
|
|
|
—
|
|
|
43
|
|
||||
Total assets
|
$
|
322,785
|
|
|
$
|
322,742
|
|
|
$
|
—
|
|
|
$
|
43
|
|
|
|
|
|
|
|
|
|
||||||||
Purchase consideration payable
|
$
|
4,994
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
4,994
|
|
Total liabilities
|
$
|
4,994
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
4,994
|
|
Description
|
December 31, 2016
|
|
Quoted Prices
in Active
Markets for
Identical Items
(Level 1)
|
|
Significant
Other
Observable
Inputs
(Level 2)
|
|
Significant
Unobservable
Inputs
(Level 3)
|
||||||||
Cash and cash equivalents
|
$
|
200,772
|
|
|
$
|
200,772
|
|
|
$
|
—
|
|
|
$
|
—
|
|
Available-for-sale securities
|
1,106
|
|
|
1,074
|
|
|
—
|
|
|
32
|
|
||||
Total assets
|
$
|
201,878
|
|
|
$
|
201,846
|
|
|
$
|
—
|
|
|
$
|
32
|
|
|
|
|
|
|
|
|
|
||||||||
Purchase consideration payable
|
$
|
4,994
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
4,994
|
|
Total liabilities
|
$
|
4,994
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
4,994
|
|
|
Three Months Ended
June 30, |
|
Six Months Ended
June 30, |
||||||||||||
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||||||
Stock options
|
$
|
2,956
|
|
|
$
|
2,890
|
|
|
$
|
6,270
|
|
|
$
|
4,939
|
|
Employee stock purchase plan
|
275
|
|
|
—
|
|
|
537
|
|
|
—
|
|
||||
Restricted stock units
|
1,904
|
|
|
635
|
|
|
3,037
|
|
|
1,507
|
|
||||
Total stock-based compensation expense
|
$
|
5,135
|
|
|
$
|
3,525
|
|
|
$
|
9,844
|
|
|
$
|
6,446
|
|
|
Three Months Ended
June 30, |
|
Six Months Ended
June 30, |
||||||||||||
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||||||
Expected volatility
|
—
|
%
|
|
49
|
%
|
|
50
|
%
|
|
47
|
%
|
||||
Expected life (in years)
|
—
|
|
|
4.8
|
|
|
4.8
|
|
|
4.8
|
|
||||
Risk-free interest rate
|
—
|
%
|
|
1.19
|
%
|
|
1.75
|
%
|
|
1.26
|
%
|
||||
Dividend yield
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||
Fair value per stock option
|
$
|
—
|
|
|
$
|
10.31
|
|
|
$
|
9.25
|
|
|
$
|
9.97
|
|
Forfeiture rate
|
—
|
%
|
|
8
|
%
|
|
8
|
%
|
|
8
|
%
|
|
Number of
Options
(in thousands)
|
|
Weighted
Average
Exercise Price
|
|
Weighted
Average
Remaining
Contractual
Term (Years)
|
|
Aggregate
Intrinsic Value
(in thousands) (1)
|
|||||
Outstanding at December 31, 2016
|
4,766
|
|
|
$
|
27.27
|
|
|
5.03
|
|
$
|
5,714
|
|
Granted
|
66
|
|
|
21.28
|
|
|
|
|
|
|||
Exercised
|
(457
|
)
|
|
15.44
|
|
|
|
|
|
|||
Forfeited
|
(112
|
)
|
|
27.27
|
|
|
|
|
|
|||
Outstanding at June 30, 2017
|
4,263
|
|
|
$
|
28.45
|
|
|
4.91
|
|
$
|
28,735
|
|
Exercisable at June 30, 2017
|
1,549
|
|
|
$
|
27.57
|
|
|
3.64
|
|
$
|
12,706
|
|
|
Number of Units
(in thousands)
|
|
Weighted Average Per Share
Grant Date Fair Value
|
||
Non-vested at December 31, 2016
|
416
|
|
$
|
31.52
|
|
Granted
|
662
|
|
$
|
33.10
|
|
Vested
|
(14)
|
|
$
|
24.74
|
|
Forfeited
|
(25)
|
|
$
|
30.62
|
|
Non-vested at June 30, 2017
|
1,039
|
|
$
|
30.75
|
|
|
June 30,
2017 |
|
December 31,
2016 |
||||
Gross accounts receivable (1)
|
$
|
370,504
|
|
|
$
|
519,175
|
|
Less reserves for:
|
|
|
|
||||
Chargebacks (2)
|
(56,580
|
)
|
|
(80,360
|
)
|
||
Rebates (2)
|
(78,593
|
)
|
|
(97,935
|
)
|
||
Product returns
|
(47,749
|
)
|
|
(43,689
|
)
|
||
Discounts and allowances
|
(8,303
|
)
|
|
(12,389
|
)
|
||
Advertising and promotions
|
(932
|
)
|
|
(688
|
)
|
||
Doubtful accounts
|
(756
|
)
|
|
(960
|
)
|
||
Trade accounts receivable, net
|
$
|
177,591
|
|
|
$
|
283,154
|
|
|
Three Months Ended
June 30, |
|
Six Months Ended
June 30, |
||||||||||||
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||||||
Gross sales
|
$
|
567,112
|
|
|
$
|
708,368
|
|
|
$
|
1,247,647
|
|
|
$
|
1,301,759
|
|
Less adjustments for:
|
|
|
|
|
|
|
|
||||||||
Chargebacks (1)
|
(237,275
|
)
|
|
(290,218
|
)
|
|
(517,437
|
)
|
|
(509,593
|
)
|
||||
Rebates, administrative and other fees (1)
|
(109,760
|
)
|
|
(102,941
|
)
|
|
(234,138
|
)
|
|
(191,289
|
)
|
||||
Product returns
|
(8,116
|
)
|
|
(18,799
|
)
|
|
(16,533
|
)
|
|
(23,086
|
)
|
||||
Discounts and allowances
|
(10,830
|
)
|
|
(13,218
|
)
|
|
(23,752
|
)
|
|
(25,171
|
)
|
||||
Advertising, promotions and others
|
(1,991
|
)
|
|
(2,458
|
)
|
|
(3,227
|
)
|
|
(3,539
|
)
|
||||
Revenues, net
|
$
|
199,140
|
|
|
$
|
280,734
|
|
|
$
|
452,560
|
|
|
$
|
549,081
|
|
|
June 30,
2017 |
|
December 31,
2016 |
||||
Finished goods
|
$
|
75,585
|
|
|
$
|
73,027
|
|
Work in process
|
12,677
|
|
|
14,719
|
|
||
Raw materials and supplies
|
93,287
|
|
|
87,047
|
|
||
Inventories, net
|
$
|
181,549
|
|
|
$
|
174,793
|
|
|
June 30,
2017 |
|
December 31,
2016 |
||||
Land and land improvements
|
$
|
18,011
|
|
|
$
|
17,410
|
|
Buildings and leasehold improvements
|
98,649
|
|
|
88,825
|
|
||
Furniture and equipment
|
173,299
|
|
|
160,546
|
|
||
Sub-total
|
289,959
|
|
|
266,781
|
|
||
Accumulated depreciation
|
(119,371
|
)
|
|
(108,425
|
)
|
||
Property, plant and equipment in service, net
|
$
|
170,588
|
|
|
$
|
158,356
|
|
Construction in progress (1)
|
106,348
|
|
|
80,048
|
|
||
Property, plant and equipment, net
|
$
|
276,936
|
|
|
$
|
238,404
|
|
|
Consumer
Health
|
|
Prescription
Pharmaceuticals
|
|
Total
|
||||||
Balances at December 31, 2016
|
$
|
16,717
|
|
|
$
|
267,576
|
|
|
$
|
284,293
|
|
Currency translation adjustments
|
—
|
|
|
761
|
|
|
761
|
|
|||
Acquisitions
|
—
|
|
|
—
|
|
|
—
|
|
|||
Impairments
|
—
|
|
|
—
|
|
|
—
|
|
|||
Dispositions
|
—
|
|
|
—
|
|
|
—
|
|
|||
Balances at June 30, 2017
|
$
|
16,717
|
|
|
$
|
268,337
|
|
|
$
|
285,054
|
|
|
Gross
Amount (1)
|
|
Accumulated
Amortization
|
|
Reclass-ifications
|
|
Gross Impairment
|
|
Net
Balance
|
|
Wtd Avg Remaining
Amortization Period
(years)
|
||||||||||
June 30, 2017
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Product licensing rights
|
$
|
745,302
|
|
|
$
|
(208,649
|
)
|
|
|
|
|
$
|
(6,468
|
)
|
|
$
|
530,185
|
|
|
10.1
|
|
IPR&D
|
173,757
|
|
|
—
|
|
|
—
|
|
|
(3,415
|
)
|
|
170,342
|
|
|
N/A - Indefinite lived
|
|||||
Trademarks
|
16,000
|
|
|
(4,874
|
)
|
|
—
|
|
|
—
|
|
|
11,126
|
|
|
18.0
|
|||||
Customer relationships
|
4,225
|
|
|
(1,928
|
)
|
|
—
|
|
|
—
|
|
|
2,297
|
|
|
8.8
|
|||||
Other intangibles
|
11,235
|
|
|
(5,184
|
)
|
|
—
|
|
|
—
|
|
|
6,050
|
|
|
5.9
|
|||||
|
$
|
950,519
|
|
|
$
|
(220,635
|
)
|
|
$
|
—
|
|
|
$
|
(9,883
|
)
|
|
$
|
720,000
|
|
|
|
December 31, 2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Product licensing rights
|
$
|
790,143
|
|
|
$
|
(182,901
|
)
|
|
$
|
9,400
|
|
|
$
|
(52,637
|
)
|
|
$
|
564,005
|
|
|
10.5
|
IPR&D
|
187,007
|
|
|
—
|
|
|
(9,400
|
)
|
|
(3,850
|
)
|
|
173,757
|
|
|
N/A - Indefinite lived
|
|||||
Trademarks
|
16,000
|
|
|
(4,244
|
)
|
|
—
|
|
|
—
|
|
|
11,756
|
|
|
18.0
|
|||||
Customer relationships
|
6,290
|
|
|
(3,863
|
)
|
|
—
|
|
|
—
|
|
|
2,427
|
|
|
9.3
|
|||||
Other intangibles
|
11,235
|
|
|
(4,326
|
)
|
|
—
|
|
|
—
|
|
|
6,909
|
|
|
6.0
|
|||||
|
$
|
1,010,675
|
|
|
$
|
(195,334
|
)
|
|
$
|
—
|
|
|
$
|
(56,487
|
)
|
|
$
|
758,854
|
|
|
|
Ratings Level
|
Index Ratings
(Moody’s/S&P)
|
Eurodollar Spread
|
ABR Spread
|
Level I
|
B1/B+ or higher
|
4.25%
|
3.25%
|
Level II
|
B2/B
|
4.75%
|
3.75%
|
Level III
|
B3/B- or lower
|
5.50%
|
4.50%
|
(In thousands)
|
2017
|
|
2018
|
|
2019
|
|
2020
|
|
Thereafter
|
|||||||||||||||
Maturities of debt
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
831,938
|
|
|
Three Months Ended
June 30, |
|
Six Months Ended
June 30, |
||||||||||||
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||||||
Net income
|
$
|
2,537
|
|
|
$
|
61,993
|
|
|
$
|
43,564
|
|
|
$
|
103,879
|
|
Convertible debt income adjustments, net of tax
|
—
|
|
|
443
|
|
|
—
|
|
|
1,047
|
|
||||
Net income adjusted for convertible debt as used for diluted earnings per share
|
$
|
2,537
|
|
|
$
|
62,436
|
|
|
$
|
43,564
|
|
|
$
|
104,926
|
|
Net income per share:
|
|
|
|
|
|
|
|
||||||||
Basic
|
$
|
0.02
|
|
|
$
|
0.51
|
|
|
$
|
0.35
|
|
|
$
|
0.86
|
|
Diluted (1)
|
$
|
0.02
|
|
|
$
|
0.50
|
|
|
$
|
0.35
|
|
|
$
|
0.83
|
|
Shares used in computing net income per share:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Weighted average basic shares outstanding
|
124,660
|
|
|
121,374
|
|
|
124,541
|
|
|
120,401
|
|
||||
Dilutive securities:
|
|
|
|
|
|
|
|
|
|
||||||
Stock option and unvested RSUs
|
534
|
|
|
1,365
|
|
|
314
|
|
|
1,474
|
|
||||
Shares issuable upon conversion of the notes
|
—
|
|
|
3,185
|
|
|
—
|
|
|
4,059
|
|
||||
Total dilutive securities
|
534
|
|
|
4,550
|
|
|
314
|
|
|
5,533
|
|
||||
Weighted average diluted shares outstanding
|
125,194
|
|
|
125,924
|
|
|
124,855
|
|
|
125,934
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Shares subject to stock options omitted from the calculation of income per share as their effect would have been anti-dilutive
|
2,268
|
|
|
2,430
|
|
|
3,991
|
|
|
2,740
|
|
(1)
|
As a result of the Company's expectation that it would likely settle all future note conversions in shares of the Company's common stock, the diluted income from continuing operations per share calculation for the periods prior to the complete conversion of the convertible debt on June 1, 2016, included the dilutive effect of convertible debt and was offset by the exclusion of interest expense and deferred financing fees related to the convertible debt of
$0.4 million
and
$1.0 million
, after-tax for the three and six month periods ended June 30, 2016.
|
|
Three Months Ended
June 30, |
|
Six Months Ended
June 30, |
||||||||||||
|
2017
|
|
2016
|
|
2017
|
|
2017
|
||||||||
Revenues, net:
|
|
|
|
|
|
|
|
||||||||
Prescription Pharmaceuticals
|
$
|
182,645
|
|
|
$
|
265,015
|
|
|
$
|
420,024
|
|
|
$
|
515,764
|
|
Consumer Health
|
16,495
|
|
|
15,719
|
|
|
32,536
|
|
|
33,317
|
|
||||
Total revenues, net
|
199,140
|
|
|
280,734
|
|
|
452,560
|
|
|
549,081
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Gross Profit:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Prescription Pharmaceuticals
|
96,104
|
|
|
164,492
|
|
|
237,423
|
|
|
319,127
|
|
||||
Consumer Health
|
6,863
|
|
|
7,281
|
|
|
14,676
|
|
|
15,663
|
|
||||
Total gross profit
|
102,967
|
|
|
171,773
|
|
|
252,099
|
|
|
334,790
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Operating expenses
|
88,437
|
|
|
79,405
|
|
|
162,736
|
|
|
154,843
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Operating income
|
14,530
|
|
|
92,368
|
|
|
89,363
|
|
|
179,947
|
|
||||
Other expenses, net
|
(7,780
|
)
|
|
(12,093
|
)
|
|
(17,287
|
)
|
|
(33,100
|
)
|
||||
|
|
|
|
|
|
|
|
||||||||
Income before income taxes
|
$
|
6,750
|
|
|
$
|
80,275
|
|
|
$
|
72,076
|
|
|
$
|
146,847
|
|
Year ending December 31,
|
Amount
|
||
2017
|
$
|
5,285
|
|
2018
|
7,328
|
|
|
2019
|
4,820
|
|
|
2020 and Beyond
|
800
|
|
|
Total
|
$
|
18,233
|
|
|
Three Months Ended
June 30, |
|
Six Months Ended
June 30, |
||||
Big 3 Wholesalers combined
:
|
2017
|
|
2016
|
|
2017
|
|
2016
|
Percentage of gross sales
|
81%
|
|
76%
|
|
80%
|
|
78%
|
Percentage of net revenues
|
62%
|
|
70%
|
|
63%
|
|
69%
|
|
June 30,
2017 |
|
December 31,
2016 |
Percentage of gross trade accounts receivable
|
85%
|
|
84%
|
|
Three Months Ended
June 30, |
|
Six Months Ended
June 30, |
||||||||||||
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||||||
Income before income taxes
|
$
|
6,750
|
|
|
$
|
80,275
|
|
|
$
|
72,076
|
|
|
$
|
146,847
|
|
Income tax provision
|
4,213
|
|
|
18,282
|
|
|
28,512
|
|
|
42,968
|
|
||||
Net income
|
$
|
2,537
|
|
|
$
|
61,993
|
|
|
$
|
43,564
|
|
|
$
|
103,879
|
|
|
|
|
|
|
|
|
|
||||||||
Income tax provision as a percentage of income before income taxes
|
62.4
|
%
|
|
22.8
|
%
|
|
39.6
|
%
|
|
29.3
|
%
|
•
|
Certain of our key products, including Ephedrine Sulfate Injection, Clobetasol Propionate Ointment and Lidocaine Ointment, have recently experienced, and may continue to experience increased competition, which has resulted in, and could continue to result in declines in both pricing and volume
|
•
|
Our growth depends on our ability to timely and efficiently develop and successfully launch and market new pharmaceutical products
|
•
|
We could experience business interruptions at our manufacturing facilities
|
•
|
We may be subject to significant disruptions or failures in our information technology systems and network infrastructures
|
•
|
We may be subject to supply disruptions and may be unable to resolve them in a timely or cost-effective manner
|
•
|
Our inability to effectively manage or support our growth
|
•
|
The loss or failure of third party manufacturers as a significant portion of our revenues are generated through the sale of these products
|
•
|
The loss or failure of any of the small number of wholesalers we use to distribute our products
|
•
|
We depend on our employees and must continue to attract and retain key personnel in order to compete successfully, and any failure to do so could hinder successful execution of our business and development plans
|
•
|
We have entered into several strategic business alliances that may not result in marketable products
|
•
|
Failure to obtain regulatory certification of our manufacturing facility in India for production of pharmaceutical products for export to the United States, as well as other regulated world markets
|
•
|
We may not achieve the anticipated benefits from our acquisitions and we may face integration difficulties
|
•
|
We become involved in legal proceedings from time to time
|
•
|
We may incur charges to earnings resulting from acquisitions
|
•
|
The Chairman of our Board of Directors, through his stock ownership and his right to nominate up to two other directors, could have an adverse effect on the market value of our stock and have substantial influence over our business strategies and policies
|
•
|
The loss of single-sourced raw materials and components used in our products
|
•
|
Sales of our products may be adversely affected by the continuing consolidation of our customer base
|
•
|
Changes in technology could render our products obsolete
|
•
|
Our branded products may become subject to increased generic competition
|
•
|
We are subject to extensive government regulations which if they change and or we are not in compliance with, could increase our costs, subject us to various obligations and fines, or prevent us from selling our products or operating our facilities
|
•
|
Changes in healthcare law and policy changes may adversely affect our business plans and results of operations
|
•
|
The FDA may require us to stop marketing certain unapproved drugs
|
•
|
Any failure to comply with the complex reporting and payment obligations under Medicare, Medicaid and other government programs may result in litigation or sanctions
|
•
|
Failure to comply with the U.S. Foreign Corrupt Practices Act could subject us to, among other things, penalties and legal expenses that could harm our reputation and have a material adverse effect on our business, financial condition and operating results
|
•
|
The FDA may authorize sales of some prescription pharmaceuticals on a non-prescription basis, which may reduce the profitability of our prescription products
|
•
|
Third parties may claim that we infringe their proprietary rights and may prevent or delay us from manufacturing and selling some of our new products
|
•
|
Our patents and proprietary rights may be challenged, circumvented or otherwise compromised by competitors, which may result in our protected products losing their market exclusivity and becoming subject to generic competition before their patents expire
|
•
|
We have previously identified, reported and remediated material weaknesses, and may identify new material weaknesses in the future
|
•
|
The restatement of our previously issued 2014 financial statements and the previous delay in our filing of 2015 financial statements has resulted in various governmental investigations and shareholder lawsuits and could result in government enforcement actions, which could have a material adverse impact on our results of operations, financial condition, liquidity, and cash flows
|
•
|
We may need to obtain additional capital to continue to grow our business
|
•
|
We may not generate cash flow sufficient to pay interest and make required principal repayments on our Term Loans
|
•
|
Our indebtedness reduces our financial and operating flexibility
|
•
|
Exercise of options and granting of restricted stock units, may have a substantial dilutive effect on our common stock
|
•
|
The risk that the proposed merger with Fresenius Kabi may not be completed in a timely manner or at all
|
•
|
The possibility that any or all of the various conditions to the consummation of the merger may not be satisfied or waived, including the failure to receive any required regulatory approvals from any applicable governmental entities (or any conditions, limitations or restrictions placed on such approvals)
|
•
|
The occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement, including in circumstances which would require Akorn to pay a termination fee or other expenses
|
•
|
The effect of the announcement or pendency of the transactions contemplated by the Merger Agreement on Akorn’s ability to retain and hire key personnel, its ability to maintain relationships with its customers, suppliers and others with whom it does business, or its operating results and business generally
|
•
|
Risks related to diverting management’s attention from Akorn’s ongoing business operations
|
•
|
The risk that shareholder litigation in connection with the transactions contemplated by the Merger Agreement may result in significant costs of defense, indemnification and liability
|
|
Three Months Ended
June 30, |
|
Six Months Ended
June 30, |
||||||||||||||||||||||||
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||||||||||||||||||
|
Amount
|
|
% of
Revenue |
|
Amount
|
|
% of
Revenue |
|
Amount
|
|
% of
Revenue
|
|
Amount
|
|
% of
Revenue
|
||||||||||||
Revenues, net:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Prescription Pharmaceuticals
|
$
|
182,645
|
|
|
91.7
|
%
|
|
$
|
265,015
|
|
|
94.4
|
%
|
|
$
|
420,024
|
|
|
92.8
|
%
|
|
$
|
515,764
|
|
|
93.9
|
%
|
Consumer Health
|
16,495
|
|
|
8.3
|
%
|
|
15,719
|
|
|
5.6
|
%
|
|
32,536
|
|
|
7.2
|
%
|
|
33,317
|
|
|
6.1
|
%
|
||||
Total revenues, net
|
199,140
|
|
|
100.0
|
%
|
|
280,734
|
|
|
100.0
|
%
|
|
452,560
|
|
|
100.0
|
%
|
|
549,081
|
|
|
100.0
|
%
|
||||
Gross profit:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Prescription Pharmaceuticals
|
96,104
|
|
|
52.6
|
%
|
|
164,492
|
|
|
62.1
|
%
|
|
237,423
|
|
|
56.5
|
%
|
|
319,127
|
|
|
61.9
|
%
|
||||
Consumer Health
|
6,863
|
|
|
41.6
|
%
|
|
7,281
|
|
|
46.3
|
%
|
|
14,676
|
|
|
45.1
|
%
|
|
15,663
|
|
|
47.0
|
%
|
||||
Total gross profit
|
102,967
|
|
|
51.7
|
%
|
|
171,773
|
|
|
61.2
|
%
|
|
252,099
|
|
|
55.7
|
%
|
|
334,790
|
|
|
61.0
|
%
|
||||
Operating expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
SG&A expenses
|
53,922
|
|
|
27.1
|
%
|
|
53,971
|
|
|
19.2
|
%
|
|
101,449
|
|
|
22.4
|
%
|
|
103,057
|
|
|
18.8
|
%
|
||||
Acquisition-related costs
|
76
|
|
|
—
|
%
|
|
136
|
|
|
—
|
%
|
|
87
|
|
|
—
|
%
|
|
333
|
|
|
0.1
|
%
|
||||
R&D expenses
|
15,877
|
|
|
8.0
|
%
|
|
8,868
|
|
|
3.2
|
%
|
|
27,167
|
|
|
6.0
|
%
|
|
18,347
|
|
|
3.3
|
%
|
||||
Amortization of intangible assets
|
15,504
|
|
|
7.8
|
%
|
|
16,430
|
|
|
5.9
|
%
|
|
30,975
|
|
|
6.8
|
%
|
|
32,948
|
|
|
6.0
|
%
|
||||
Impairment of intangible assets
|
3,058
|
|
|
1.5
|
%
|
|
—
|
|
|
—
|
%
|
|
3,058
|
|
|
0.7
|
%
|
|
158
|
|
|
—
|
%
|
||||
Operating income
|
$
|
14,530
|
|
|
7.3
|
%
|
|
$
|
92,368
|
|
|
32.9
|
%
|
|
$
|
89,363
|
|
|
19.7
|
%
|
|
$
|
179,947
|
|
|
32.8
|
%
|
Other expense, net
|
(7,780
|
)
|
|
(3.9
|
)%
|
|
(12,093
|
)
|
|
(4.3
|
)%
|
|
(17,287
|
)
|
|
(3.8
|
)%
|
|
(33,100
|
)
|
|
(6.0
|
)%
|
||||
Income before income taxes
|
6,750
|
|
|
3.4
|
%
|
|
80,275
|
|
|
28.6
|
%
|
|
72,076
|
|
|
15.9
|
%
|
|
146,847
|
|
|
26.7
|
%
|
||||
Income tax provision
|
4,213
|
|
|
2.1
|
%
|
|
18,282
|
|
|
6.5
|
%
|
|
28,512
|
|
|
6.3
|
%
|
|
42,968
|
|
|
7.8
|
%
|
||||
Net income
|
$
|
2,537
|
|
|
1.3
|
%
|
|
$
|
61,993
|
|
|
22.1
|
%
|
|
$
|
43,564
|
|
|
9.6
|
%
|
|
$
|
103,879
|
|
|
18.9
|
%
|
(amounts in thousands)
|
Six Months Ended
June 30, |
||||||
|
2017
|
|
2016
|
||||
OPERATING ACTIVITIES:
|
|
|
|
||||
Consolidated net income
|
$
|
43,564
|
|
|
$
|
103,879
|
|
Adjustments to reconcile consolidated net income to net cash provided by operating activities:
|
|
|
|
|
|
||
Depreciation and amortization
|
42,212
|
|
|
44,111
|
|
||
Amortization of debt financing costs
|
2,608
|
|
|
8,152
|
|
||
Impairment of intangible assets
|
8,079
|
|
|
158
|
|
||
Non-cash stock compensation expense
|
9,844
|
|
|
6,446
|
|
||
Non-cash interest expense
|
—
|
|
|
764
|
|
||
Income from Available for sale securities
|
(3,032
|
)
|
|
—
|
|
||
Deferred income taxes, net
|
(2,341
|
)
|
|
(9,724
|
)
|
||
Loss on sale of available-for-sale securities
|
196
|
|
|
45
|
|
||
Other
|
(288
|
)
|
|
(780
|
)
|
||
Changes in operating assets and liabilities:
|
|
|
|
|
|
||
Trade accounts receivable
|
105,848
|
|
|
(54,296
|
)
|
||
Inventories, net
|
(6,225
|
)
|
|
(2,652
|
)
|
||
Prepaid expenses and other current assets
|
3,076
|
|
|
(23,421
|
)
|
||
Trade accounts payable
|
(13,465
|
)
|
|
4,778
|
|
||
Accrued expenses and other liabilities
|
(30,051
|
)
|
|
(41,383
|
)
|
||
NET CASH PROVIDED BY OPERATING ACTIVITIES
|
$
|
160,025
|
|
|
$
|
36,077
|
|
(amounts in thousands)
|
Six Months Ended
June 30, |
||||||
|
2017
|
|
2016
|
||||
INVESTING ACTIVITIES:
|
|
|
|
|
|
||
Proceeds from disposal of assets
|
$
|
4,811
|
|
|
$
|
5,966
|
|
Payments for intangible assets
|
(200
|
)
|
|
(3,375
|
)
|
||
Purchases of property, plant and equipment
|
(50,072
|
)
|
|
(29,726
|
)
|
||
NET CASH USED IN INVESTING ACTIVITIES
|
$
|
(45,461
|
)
|
|
$
|
(27,135
|
)
|
(amounts in thousands)
|
Six Months Ended
June 30, |
||||||
|
2017
|
|
2016
|
||||
FINANCING ACTIVITIES:
|
|
|
|
|
|
||
Proceeds from the exercise of stock options
|
$
|
6,897
|
|
|
$
|
6,176
|
|
Debt financing costs
|
—
|
|
|
(5,128
|
)
|
||
Debt payments
|
—
|
|
|
(200,000
|
)
|
||
NET CASH PROVIDED BY(USED IN) FINANCING ACTIVITIES
|
$
|
6,897
|
|
|
$
|
(198,952
|
)
|
•
|
The announcement or pendency of the Merger may impede Akorn’s ability to retain and hire key personnel, its ability to maintain relationships with its customers, suppliers and others with whom it does business, or its operating results and business generally;
|
•
|
The attention of our employees and management may be diverted due to activities related to the Merger, which may affect our business operations;
|
•
|
Matters relating to the transactions (including integration planning) may require substantial commitments of time and resources by Akorn management, which could harm our relationships with our employees, customers, distributors, suppliers or other business partners, and may result in a loss of or a substantial decrease in purchases by our customers;
|
•
|
The Merger Agreement restricts us from engaging in certain actions without the approval of Fresenius Kabi, which could prevent us from pursuing certain business opportunities outside the ordinary course of business that arise prior to the closing of the Merger;
|
•
|
The Merger Agreement contains provisions that could discourage a potential competing acquirer of Akorn;
|
•
|
The directors and executive officers of Akorn have interests in the Merger that may be different from, or in addition to, those of other Akorn shareholders, which could have influenced their decisions to support or approve the Merger; and
|
•
|
Shareholder litigation in connection with the transactions contemplated by the Merger Agreement may result in significant costs of defense, indemnification and liability.
|
|
AKORN, INC.
|
|
|
|
|
|
/s/ DUANE A. PORTWOOD
|
|
|
Duane A. Portwood
|
|
|
Chief Financial Officer
|
|
|
(on behalf of the registrant and as its
Principal Financial Officer)
|
1 Year Akorn Chart |
1 Month Akorn Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions